Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

MGUS and SMM Plasma Cells Exhibit a Senescence-like Phenotype and Accumulation of Transposable Elements That May Contribute to Disease Progression

Gabriel Alvares Borges, Angelo Jose Guilatco, Christine M. Hachfeld, Ming Ruan, Sonya Royzenblat, Ming Xu, Claire M. Edwards, Marta Diaz-delCastillo, Thomas L. Andersen, Taxiarchis Kourelis, Tamar Tchkonia, James L. Kirkland, Matthew T. Drake, Megan Weivoda

Blood (2022) 140 (Supplement 1): 9966–9967.

https://doi.org/10.1182/blood-2022-170571

Published: 2022

Journal Articles

Bone Marrow Microenvironmental Overexpression of DKK1, HGF, Frizzled-Related Protein B, and Syndecan-1 Are Associated with the Degree of Osteolytic Bone Disease in Multiple Myeloma Patients

Jacob Haaber, Gitte Birk Kerndrup, Maria Lyng, Thomas L. Andersen, Niels Pallisgaard, Niels Abildgaard

Blood (2008) 112 (11): 5139.

https://doi.org/10.1182/blood.V112.11.5139.5139

Published: 2008

Journal Articles

High Dose Simvastatin Has No Beneficial Effect on Markers of Bone Turn-Over in Multiple Myeloma.

Teis E. Sondergaard, MSc, Per T. Pedersen, MD, Thomas L. Andersen, MSc, Thomas Lund, MD, Patrick Garnero, PhD, Jean-Marie Delaisse, PhD, Torben Plesner, MD

Blood (2007) 110 (11): 4824.

https://doi.org/10.1182/blood.V110.11.4824.4824

Published: 2007

Journal Articles

Bortezomib Protects Osteoblasts from Glucocorticoid-Induced Damage, and Enhances Glucocorticoid-Induced Toxicity Against Osteoclasts and Myeloma Cells.

Kent Soe, PhD, Thomas L. Andersen, MSc, Katarzyna Kupisiewicz, MSc, Torben Plesner, MD, Jean-Marie Delaisse, PhD

Blood (2007) 110 (11): 3523.

https://doi.org/10.1182/blood.V110.11.3523.3523

Published: 2007

Journal Articles

Bortezomib Transiently Inhibits Osteoclast Resorptive Activity in Cell Culture Conditions Mimicking In Vivo Intermittent Treatment.

Patrice Boissy, PhD, Thomas Lund, MD, Thomas L. Andersen, MSc, Torben Plesner, MD, Jean-Marie Delaisse, PhD

Blood (2006) 108 (11): 3508.

https://doi.org/10.1182/blood.V108.11.3508.3508

Published: 2006

Journal Articles

Interactions between Myeloma Cells and Osteoclasts Are Controlled by Unique Histological Structures Involving Vascular Compartments.

Thomas L. Andersen, MSc, Katarzyna E. Skorzynska, MD, Teis E. Sondergaard, MSc, Trine Plesner, MD, Ellen Hauge, MD, Juha Risteli, MD, Torben Plesner, MD, Jean-Marie Delaisse, PhD

Blood (2005) 106 (11): 2513.

https://doi.org/10.1182/blood.V106.11.2513.2513

Published: 2005

NARROW

MGUS and SMM Plasma Cells Exhibit a Senescence-like Phenotype and Accumulation of Transposable Elements That May Contribute to Disease Progression

Bone Marrow Microenvironmental Overexpression of DKK1, HGF, Frizzled-Related Protein B, and Syndecan-1 Are Associated with the Degree of Osteolytic Bone Disease in Multiple Myeloma Patients

High Dose Simvastatin Has No Beneficial Effect on Markers of Bone Turn-Over in Multiple Myeloma.

Bortezomib Protects Osteoblasts from Glucocorticoid-Induced Damage, and Enhances Glucocorticoid-Induced Toxicity Against Osteoclasts and Myeloma Cells.

Bortezomib Transiently Inhibits Osteoclast Resorptive Activity in Cell Culture Conditions Mimicking In Vivo Intermittent Treatment.

Interactions between Myeloma Cells and Osteoclasts Are Controlled by Unique Histological Structures Involving Vascular Compartments.

Email alerts

ASH Publications

American Society of Hematology

MGUS and SMM Plasma Cells Exhibit a Senescence-like Phenotype and Accumulation of Transposable Elements That May Contribute to Disease Progression

Bone Marrow Microenvironmental Overexpression of DKK1, HGF, Frizzled-Related Protein B, and Syndecan-1 Are Associated with the Degree of Osteolytic Bone Disease in Multiple Myeloma Patients

High Dose Simvastatin Has No Beneficial Effect on Markers of Bone Turn-Over in Multiple Myeloma.

Bortezomib Protects Osteoblasts from Glucocorticoid-Induced Damage, and Enhances Glucocorticoid-Induced Toxicity Against Osteoclasts and Myeloma Cells.

Bortezomib Transiently Inhibits Osteoclast Resorptive Activity in Cell Culture Conditions Mimicking In Vivo Intermittent Treatment.

Interactions between Myeloma Cells and Osteoclasts Are Controlled by Unique Histological Structures Involving Vascular Compartments.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only